Carl Gay
Internal Medicine · Houston, TXNPI 1417392770
Payments from drug & device makers
Across 148 payments — averaging $41,573 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3M
- Amgen$2M
- Merck$448K
- Astrazeneca UK Limited$335K
- F. Hoffmann-la Roche AG$184K
- Genentech, Inc.$95K
- plus $141K from 15 others
Across 5 payments — averaging $435.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
- Amgen$24
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $2,969,252 |
| Amgen | 6 | $1,980,324 |
| Merck | 14 | $448,169 |
| Astrazeneca UK Limited | 22 | $335,013 |
| F. Hoffmann-la Roche AG | 7 | $183,535 |
| Genentech, Inc. | 3 | $95,298 |
| Biontech SE | 9 | $74,497 |
| Jazz Pharmaceuticals Inc. | 20 | $16,797 |
| AstraZeneca | 18 | $15,772 |
| Roche Products Limited | 4 | $8,943 |
| G1 Therapeutics, Inc. | 5 | $6,948 |
| Catalyst Pharmaceuticals, Inc. | 3 | $3,500 |
| Beigene USA, Inc. | 1 | $3,250 |
| Boehringer Ingelheim | 3 | $2,775 |
| Daiichi Sankyo Inc. | 2 | $2,706 |
| Beone Medicines USA, Inc. | 1 | $2,400 |
| Organon | 1 | $1,384 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,300 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $820 |
| Janssen Scientific Affairs, LLC | 1 | $102 |
| Novartis | 1 | $19 |
How this compares
$6,152,804 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.